Tisento Therapeutics
Series A in 2023
Tisento Therapeutics, based in Massachusetts, specializes in developing innovative medicines to address diseases with substantial unmet medical needs. Its primary focus is on treating Mitochondrial Encephalomyopathy with Lactic Acidosis and Stroke (MELAS), a severe mitochondrial disorder. The company's therapies aim to improve various aspects of the disease, including neuronal and mitochondrial function, cerebrovascular hemodynamics, and inflammatory processes, ultimately aiming to provide swift and effective treatment for patients.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.